Approach: Islet-targeted immunotherapies for safer, durable treatments
Strategic Area: Immunotherapies
T1D Funding Impact: Catalyzing the creation of a T1D-focused program using a powerful platform (TO BE ACQUIRED BY MERCK IN 2021)
Strategic Area: Immunotherapies
T1D Funding Impact: Catalyzing the creation of a T1D-focused program using a powerful platform (TO BE ACQUIRED BY MERCK IN 2021)
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $138M
Founded date: 2017
Investors 3
| Date | Name | Website |
| - | T1D Fund | t1dfund.or... |
| - | Access Bio... | accessbio-... |
| - | RA Capital... | racap.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 03.04.2020 | Series B | $80M | - |
| 18.01.2018 | Series A | $58M | - |
Mentions in press and media 15
| Date | Title | Description |
| 03.04.2020 | Funding roundup: Pandion Therapeutics raises $80M for autoimmune disease treatment | That bodes good news for the future, though it may be slow-going for many startups over the coming months. Here are some highlights from those that closed funding rounds this week: Pandion Therapeutics Funding: $80 million Headquarters: Cam... |
| 01.04.2020 | Pandion Therapeutics Announces Close of $80 Million Series B | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pandion Therapeutics, Inc., a clinical-stage, privately-held biotechnology company developing modular protein therapeutics for autoimmune disease, today announced that it has closed an $80 million Series B... |
| 01.04.2020 | Pandion Therapeutics Announces Close of $80 Million Series B Financing | - |
| 01.04.2020 | OrbiMed Joins $80M Series B for Pandion Therapeutics | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pandion Therapeutics, Inc., a clinical-stage, privately-held biotechnology company developing modular protein therapeutics for autoimmune disease, today announced that it has closed an $80 million Series B... |
| 01.04.2020 | Pandion Therapeutics Closes $80M Series B Financing | Pandion Therapeutics, Inc., a Cambridge, MA-based clinical-stage, biotechnology company developing modular protein therapeutics for autoimmune disease, closed an $80m Series B financing. The round was led by Access Biotechnology and Boxer C... |
| 01.04.2020 | Pandion Therapeutics Closes $80M in Series B | CAMBRIDGE, MA, Pandion Therapeutics announced that it has closed an $80 million Series B financing led by Access Biotechnology and Boxer Capital. >> Click here for more funding data on Pandion Therapeutics >> To export Pandi... |
| 01.04.2020 | Pandion Therapeutics scores $80M to drive autoimmune programs through clinic | Since it uncloaked two years ago, Pandion has teamed up with Astellas on bispecific drugs for Type 1 diabetes and Therapeutics has pushed its lead program into the clinic. Now, it’s reeling in another $80 million to test that treatment in p... |
| 20.12.2018 | Daily funding roundup - December 20th, 2018 | Layer1 raised $2.1M; Gamelearn raised $5M; BacklotCars raised $8; DrChrono raised $10M Layer1: Layer1 is a cryptoasset investment and infrastructure platform. One months-old, San Francisco-based company has raised $2.1 million in funding fr... |
| 20.12.2018 | Term Sheet — Thursday, December 20 | 5 Qs WITH A DEALMAKER Earlier this month, French President Emmanuel Macron invited a contingent of 40 U.S.-based venture capitalists and limited partners to come talk tech. Paid Content Securing the enterprise without boundaries From ExtraH... |
| 19.01.2018 | Term Sheet — Friday, January 19 | CRYPTO HYBRIDS Happy Friday, Term Sheet readers. Paid Content You can't secure what you can't see From ExtraHop HOT TAKES: Yesterday, I wrote about storage startup Omni and its decision to take the majority of its $25 million fundraise in R... |
Show more